The last time I wrote about Silence Therapeutics plc (SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article ...
New findings point to an opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially including those involved in cancer. In everyday life, when things turn out ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
In drug discovery, very little of what’s learned from one project can typically be carried over to the next. “For every new target you go after with a small molecule, you basically start from scratch, ...
Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...
SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...
New research from Dr. Seungjae Lee, Dr. Eric Lai, and their collaborators points to a potential opportunity to improve therapies that use small RNAs to silence disease-causing genes, potentially ...
A formamide modification (yellow) to a therapeutic agent siRNA (blue) prevents siRNA to bind to non-target mRNA, which allows for treatment with less side effects. Small interfering RNA (siRNA) drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results